Draft Guidance Eases Endpoint For Chronic Hepatitis C Trials

Clinical Trials Advisor
Sponsors of direct-acting antiviral (DAA) drugs for the treatment of chronic hepatitis C got some relief in the form of a relaxed endpoint for use in late-stage studies.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00